Cancer immunotherapy drugs take longer to benefit patients and may not result in the rapid tumor shrinkage often seen with chemotherapy or targeted therapies even though they can prolong survival, experts say. This was evident in the Yervoy study, where patients treated with the drug reported a median time to tumor progression of 2.8 months compared to 2.6 months for the chemotherapy arm. The rate of tumor shrinkage attributed to Yervoy-dacabazine was 15% compared to 10% for dacarbazine alone.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

FDA Approves Roche, Curis Skin-Cancer Drug

Third Time's The Charm for Approval of Amylin Diabetes Drug

FDA Approves Regeneron Drug to Treat Common Cause of Blindness

FDA Approves Regeneron Drug to Treat Common Cause of Blindness

FDA Revokes Roche Avastin Approval in Breast Cancer

FDA Revokes Roche Avastin Approval in Breast Cancer

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market